CDP-870 (certolizumab) in rheumatoid arthritis

Bibliography

• FELTS W, YELIN E: The economic impact of the rheumatic diseases in the United States. J. Rheumatol (1989) 16(7):867–884.
   PubMed Web of Science ®Google Scholar
• THORNTON SC, POR SB, PENNY R, RICHTER M, SHELLEY L, BREIT SN: Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha. Clin. Exp. Immunol (1991) 86(1):79–86.
   PubMed Web of Science ®Google Scholar
• OLD LJ: Tumor necrosis factor. Sci. Am. (1988) 258(5):59–60, 69–75.
   Google Scholar
• BEUTLER BA: The role of tumor necrosis factor in health and disease. J. Rheumatol Suppl (1999) 57:16–21.
   PubMedGoogle Scholar
• ••Good review of the biology of TNF-a.
   Google Scholar
• CHU CQ, FIELD M, FELDMANN M, MAINI RN: Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. (1991) 34(9):1125–1132.
   PubMed Web of Science ®Google Scholar
• •Evidence for localisation of TNF-a in the synovium and blood of RA patients.
   Google Scholar
• KEFFER J, PROBERT L, CAZLARIS H et al.: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. (1991) 10(13):4025–4031.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1992) 89(20):9784–9788.
   PubMed Web of Science ®Google Scholar
• •Effectiveness of anti-TNF-a therapy in a murine model of inflammatory arthritis.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344(8930):1105–1110.
   PubMed Web of Science ®Google Scholar
• TAK PP, TAYLOR PC, BREEDVELD FC et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. (1996) 39(7):1077–1081.
   PubMed Web of Science ®Google Scholar
• MPOFU S, FATIMA F, MOOTS RJ: Anti-TNFa therapies: they are all the same (aren't they?). Rheumatology (Word) (2005) 44(3):271–273.
   PubMed Web of Science ®Google Scholar
• ••Good discussion of structural,pharmacokinetic and biological differences in commercially available anti-TNF-a agents.
   Google Scholar
• CHOY EH, HAZLEMAN B, SMITH M et al.: Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) (2002) 41(10):1133–1137.
   PubMed Web of Science ®Google Scholar
• ••Description of molecular structure,manufacture, pharmacokinetics, pharmacodynamics, dose ranging, adverse events and benefits of CDP-870 in RA. So far, the only Phase II study of CDP-870 in RA published in a peer-reviewed journal.
   Google Scholar
• ROSE-JOHN S, SCHOOLTINK H: CDP-870. Celltech/Pfizer. Curr. Opin. Investig Drugs (2003) 4(5):588–592.
   PubMedGoogle Scholar
• CELLTECH GROUP PLC: Celltech announces manufacturing agreement with Biochemie. Press Release (12 September 2002).
   Google Scholar
• PLASSE TF: Anti-inflammatory therapeutics (part II), IDdb Meeting Report. The Hatton, London, UK (14–15 January 2002).
   Google Scholar
• ZHU Z: Engineered antibodies accelerating drug discovery and development (part I), IDdb Meeting Report. Philadelphia, PA, USA (22–23 October 2001).
   Google Scholar
• CELLTECH GROUP PLC: Celltech regains full rights to CDP 870 from Pfizer. Press Release (1 December 2003).
   Google Scholar
• CELLTECH CHIROSCIENCE PLC: Positive results with Celltech Chiroscience's CDP-870 in Phase II rheumatoid arthritis study. Press Release (25 November 1999).
   Google Scholar
• PHARMACIA CORP.: Results presented on Phase II study of investigational drug to test the reduction of signs and symptoms of rheumatoid arthritis. Press Release (12 November 2001).
   Google Scholar
• KEYSTONE E, CHOY E, KALDEN J et al.: CDP870, a novel, PEGYLATED, humanized TNF- inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA) - Late breaking abstract.
   Google Scholar
• EMERY P, SMOLEN J, CHOY E et al.: CDP-870, a novel, pegylated, humanized, tumor necrosis factor alpha (TNF-a) inhibitor improves HROOL. EULAR (2002).
   Google Scholar
• •Phase II study of CDP-870 in RA.
   Google Scholar
• CELLTECH GROUP PLC: Overview of Celltech R&D. Company Presentation (17 October 2002).
   Google Scholar
• CELLTECH GROUP PLC: Preliminary announcement of results for year ended 31 December 2002. Press Release (18 March 2003).
   Google Scholar
• SCHREIBER S, RUTGEERTS P, FEDORAK R, KHALIQ-KAREEMI M, KAMM M, PATEL J: CDP870, a humanized anti-TNF antibody fragment induces clinical response with remission in patients with active Crohn's disease. The CDP870 Crohn's disease study group. Gastroenterology (2003) 124(4):468 (abstract).
   Google Scholar
• WINTER TA, WRIGHT J, GHOSH S, JAHNSEN J, INNES A, ROUND P: Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment. Pharmacol Ther. (2004) 20(11-12):1337–1346.
   PubMed Web of Science ®Google Scholar
• •Phase II dose-ranging trial of intravenous CDP-870 in CD.
   Google Scholar
• KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Lancet (2004) 363(9410):675–681.
   Google Scholar